Abstract
Interferons have enjoyed increasing interest since their discovery in 1957 (1) and may be regarded as prototype biological substances in the systemic treatment of cancer. Besides natural interferon (IFN) alpha produced by leukocyte suspensions, highly purified material produced by recombinant DNA technology became available in 1981 (2–4). These different types of IFN have been shown to be effective against various malignancies. The most impressive results have been achieved in hematologic disorders (5–8). However, data are difficult to compare since in these phase I and II trials different products were used and, moreover, administered in different routes, doses and schedules. Here we will review clinical experience with IFNs in the treatment of hairy cell leukemia and chronic myelogenous leukemia.
Preview
Unable to display preview. Download preview PDF.
References
Isaacs A, Lindenmann J: Virus interference. I. The interferon. Proc R Soc Ser B 1957 (147):258–267
Goeddel DV, Yelverton E, Ullrich A et al.:Human leukocyte interferon produced by E. coli is biologically active. Nature (Lond) 1980 (287):411–416
Nagata S, Taira H, Hall A et al.: Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature (Lond) 1980 (284):316–320
Pestka S: Interferon: A decade of accomplishments, foundations of the future in research and therapy. Semin Hematol 1986 (23):27–37
Oldham RK: Biologicals for cancer treatment: Interferons. Hosp Prac 1985:71–91
Niederle N, Schmidt CG: Klinische Erfahrungen mit Interferon in der Tumortherapie. In: Schuff-Werner P, Pfizenmaier K (eds) Entwicklung, Pruefung und Anwendung von biologisch aktiven Substanzen in der Krebstherapie. Aktuelle Onkologie 1985 (24):116–136, Muenchen, Bern, Wien: Zuckschwerdt-Verlag
Krown SE: Interferons and interferon inducers in cancer treatment. Semin Oncol 1986 (13):207–217
Goldstein D, Laszlo J: Interferon therapy in cancer: From imaginon to interferon. Cancer Res 1986 (46):4315- 4329
Ewald O: Die leukaemische Retikuloendotheliosis. Dtsch Arch Klin Med 1923 (142):222–228
Bouroncle BA, Wiseman BK, Doan CA: Leukemic reticuloendotheliosis. Blood 1958 (13):609–630
Catovsky D: Prolymphocyte and hairy cell leukemias. In: Gunz FW, Henderson ES (eds) Leukemia, 4 ed. 1983:759–781, New York-London: Grüne and Stratton
Flandrin G, Sigaux F, Sebahoun G et al.: Hairy cell leukemia: Clinical presentation and follow-up of 211 patients. Semin Oncol 1984 (11) (Suppl 2):458–471
Mende S, Fuelle H-H, Weissenfels I: Diagnose und Differentialdiagnose der Haarzell-Leukaemie (“Hairy cell leukaemia”; “Leukaemische Retikuloendotheliose”). Blut 1975 (30):163–174
Catovsky D, Pettit JE, Galetto J et al.: The B-lymphocytic nature of the hairy cell of leukaemic reticuloendotheliosis. Brit J Haematol 1974 (26):29–37
Golde DW, Stevens RH, Quan SG, Saxon A: Immunoglobulin synthesis in hairy cell leukaemia. Brit J Haematol 1977 (35):359–365
Jansen J, Schuit HRE, Van Zwet TL et al.: Hairy cell leukaemia: a B-lymphocytic disorder. Brit J Haematol 1979 (42):21–33
Jansen J, Den Ottolander GJ, Schuit HRE et al.: Hairy cell leukemia: Its place among the chronic B cell leukemias. Semin Oncol 1984 (11):386–393
Melo JV, San Miguel JF, Moss VE et al.: The membrane phenotype of hairy cell leukemia: A study with monoclonal antibodies. Semin Oncol 1984 (11):381–385
Korsmeyer SJ, Greene WC, Cossman J et al.: Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc Natl Acad Sei USA 1983 (80):4522–4526
Yam LT, Li CY, Lam KW: Tartrate-resistant acid phosphatase isoenzyme in the reticulum cells of leukemic reticuloendotheliosis. N Engl J Med 1971 (284):357–360
Schaefer HE, Hellriegel KP, Zach J et al.: Zytochemischer Polymorphismus der sauren Phosphatase bei Haarzell Leukaemie. Blut 1975 (31):365–370
Golomb HM: Hairy cell leukemia: Lessons learned in twenty-five years. J Clin Oncol 1983 (1):652–656
Stewart DJ, Bodey GP: Infections in hairy cell leukemia (leukemic reticuloendotheliosis). Cancer 1981 (47):801–805
Jansen J, Hermans J: for the Collaborative Study Group: Splenectomy in hairy cell leukemia: A retrospective multicenter analysis. Cancer 1981 (47): 2066–2076
Magee JM, McKenzie S, Filippa DA et al.: Hairy cell leukemia. Durability of response to splenectomy in 26 patients and treatment of relapse with androgens in six patients. Cancer 1985 (56):2557–2562
Van Norman AS, Nagorney DM, Martin JK et al.: Splenectomy of hairy cell leukemia. A clinical review of 63 patients. Cancer 1986 (57):644–648
Golde DW, Jacobs AD, Glaspy JA: Hairy cell leukemia: Biology and treatment. Semin Hematol 1986 (23, Suppl 1):472–478
Jansen J, den Ottolander GJ, Holdrinet RSG et al.: Prognosis and therapy in hairy cell leukemia. Semin Oncol 1984 (11, Suppl 2):472–478
McCarthy D, Catovsky D: Response to doxorubicin in hairy cell leukemia (leukemic reticuloendotheliosis). Blood 1979 (54):298–304
Stewart DJ, Benjamin RS, McCredie KB: The effectiveness of rubidazone in hairy cell leukemia (leukemic reticuloendotheliosis). Blood 1979 (54):298–304
Golomb HM, Schmidt K, Vardiman JW: Chlorambucil therapy of twenty-four post-splenectomy patients with progressive hairy cell leukemia. Semin Oncol 1984 (11, Suppl 2):502–506
Yam LT, Klock JC, Mielke CH: Therapeutic leukapheresis in hairy cell leukemia: Review of literature and personal experience. Semin Oncol 1984 (11, Suppl 2):493–501
Cheever MA, Fefer A, Greenberg PD et al.: Identical twin bone marrow transplantation for hairy cell leukemia. Semin Oncol 1984 (11, Suppl 2):511–513
Calvo F, Castaigne S, Sigaux F et al.: Intensive chemotherapy of hairy cell leukemia in patients with aggressive disease. Blood 1985 (65):115–119
Quesada JR, Reuben J, Manning JT et al.: Alpha interferon for induction of remission in hairy cell leukemia. N Engl J Med 1984 (310):15–18
Porzsolt F, Thomä J, Unsold W et al.: Platelet-adjusted IFN dosage in the treatment of advanced hairy cell leukemia. Blut 1985 (51)73–82
Hofmann V, Fehr J, Sauter C et al.: Hairy cell leukemia: An interferon deficient disease? Cancer Treat Rev 1985 (12, Suppl B):33–37
Worman CP, Catovsky D, Bevan PC et al.: interferon is effective in hairy-cell leukaemia. Brit J Haematol 1985 (60):759–763
Huber C, Flener R, Gastl G: lnterferon-alpha-2c in the treatment of advanced hairy cell leukaemia. Results of a phase II trial. Oncology 1985 (42, Suppl 1):7–9
Quesada JR, Gutterman JU, Hersh EM: Treatment of hairy cell leukemia with alpha interferons. Cancer 1986 (57):1678–1680
Quesada JR, Hersh EM, Manning J et al.: Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood 1986 (68):493–497
Golomb HM, Jacobs A, Fefer A et al.: Alpha-2 interferon therapy of hairy-cell leukemia: A multicenter study of 64 patients. J Clin Oncol 1986 (4):900–905
Flandrin G, Sigaux F, Castaigne S et al.: Treatment of hairy cell leukemia with recombinant alpha interferon. I. Quantitative study of bone marrow changes during the first months of treatment. Blood 1986 (67):817–820
Niederle N, KLoke O, Nowrousian MR et al.: Efficacy of gamma and alpha interferon in the treatment of hairy cell leukemia. J Cancer Res Clin Oncol 1986 (111, Suppl):40
Foon KA, Maluish AE, Abrams PG et al.: Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Am J Med 1986 (80):351–356
Ehmann WC, Silber R: Recombinant alpha-2 interferon for treatment of hairy cell leukemia without prior splenectomy. Am J Med 1986 (80):1111 -1114
Smalley RV, Tuttle RL, Whisnant JK et al.: Effectiveness of Wellferon at a dose of 0.2 MU/m2 in the treatment of hairy cell leukemia. Blood 1986 (68, Suppl 1):233a
von Wussow P, Hill W, Diedrich H et al.: Low-dosage interferon alpha therapy of hairy cell leukemia. Blut 1986 (53):214
Huber C, Aulitzky W, Tilg H et al.: Studies on the optimal dose and the mode of action of interferon alpha in the treatment of hairy cell leukemia (HCL) Leukemia (in press)
Pralle H, Zwingers T, Boedewadt S et al.: A prospective multicenter trial with human recombinant interferon alpha-2c (Hr-lfn alpha 2c) in hairy cell leukemia (HCL) before and after splenectomy. Leukemia (in press)
Niederle N, Doberauer C, Kloke O et al.: Efficacy of gamma and alpha interferon on hairy cell leukemia. Klin Wochenschr (in press)
Castaigne S, Sigaux F, Canted K et al.: Interferon alpha in the treatment of hairy cell leukemia. Cancer 1986 (57):1681–1684
Aulitzky W, Gastl G, Tilg H et al.: Recurrence of hairy cell leukemia upon discontinuation of IFN treatment. Blut 1986 (53):215
Ratain MJ, Golomb HM, Vardiman JW et al.: Duration of response of hairy cell leukemia after treatment with interferon alpha-2b. Blood 1986 (68, Suppl 1):229a
Gastl G, Aulitzky W, Leiter E et al.: Alpha-interferon induces remission in hairy cell leukemia without enhancement of natural killing. Blut 1986 (52):273–279
Paganelli KA, Evans SS, Han T et al.: B cell growth factor-induced proliferation of hairy cell lymphocytes and inhibition by type I interferon in vitro. Blood 1986 (67):937–942
Porzsolt F, Janik R, Heil G et al.: Deficient IFN alpha production in hairy cell leukemia. Blut 1986 (52):185–190
Stryckmans PA, Huygen K, Vanhaelen C et al.: In vitro production of alpha and gamma interferon by blood cells of patients with hairy cell leukemia. Blood 1986 (68, Suppl 1): 181a
Lepe-Zuniga JL, Quesada JR, Gutterman JU: Deficiency of production of alpha interferon in patients with active hairy cell leukemia and its restoration after complete remission. Blood 1986 (68, Suppl 1): 202a
Billard C, Sigaux F, Castaigne S et al.: Treatment of hairy cell leukemia with recombinant alpha interferon II. In vivo down-regulation of alpha interferon receptors on tumor cells. Blood 1986 (67):821–826
Clark RH, Dimitrov NV, Axelson JA et al.: Intermittent alpha-leukocyte interferon in the treatment of hairy cell leukemia. Blood 1986 (68, Suppl 1):220a
Porzsolt F: Primary treatment of hairy cell leukemia: Should IFN-therapy replace splenectomy? Blut 1986 (52):265–272
Ratain MJ, Vardiman JW, Golomb HM: Prognostic variables in hairy cell leukemia following splenectomy as initial therapy. Blood 1986 (68, Suppl 1):205a
Spiers ASD, Parekh SJ, Bishop MB: Hairy-cell leukemia: Induction of complete remission with pentostatin (2’- deoxycoformycin). J Clin Oncol 1984 (2):1336–1342
Foon KA, Nakano GM, Koller CA et al.: Response to 2’deoxycoformycin after failure of interferon-alpha in nonsplenectomized patients with hairy cell leukemia. Blood 1986 (68):297–300
Ho AD, Dietz G, Trede I et al.: Enzymes of purine metabolism in hairy cell leukemia. Cancer 1986 (58):96–99
Dameshek W: Some speculations on the myeloproliferative syndromes. Blood 1951 (6):372–375
Fialkow PJ, Jakobson RJ, Papayannopoulou T: Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Amer J Med 1977 (63):125–130
Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 1960 (132):1497
Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (Lond) 1973 (243):290–293
Sandberg A: Chromosomes and causation of human cancer and leukemia. XL. The Ph’ and other translocations in CML. Cancer 1980 (46):2221–2226
Sokal JE, Gomez GA: The Philadelphia chromosome and Philadelphia chromosome mosaicism in chronic granulocytic leukemia. J Clin Oncol 1986 (4):104–111
Heisterkamp N, Stephenson JR, Groffen J et al.: Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature (Lond) 1983 (306):239–242
Bartram CR, de Klein A, Hagemeijer A et al.: Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983 (306):277–280
Shtivelman E, Lifshitz B, Gale RP et al.: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature (Lond) 1985 (315):550–554
Stam K, Heisterkamp N, Grosveld G et al.: Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. N Engl J Med 1985 (313):1429–1433
Kloetzer W, Kurzrock R, Smith L et al.: The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology 1985 (140):230–238
Canellos GP: Chronic granulocytic leukemia. Med Clin N Amer 1976 (60):1001–1018
Koeffler HP, Golde DW: Chronic myelogenous leukemia - New concepts (First of two parts). N Engl J Med 1981 (304):1201–1209
Silver RT, Gale RP: Chronic myeloid leukemia. Amer J Med 1986 (80):1137–1147
Minot GR, Buckman TE, Isaacs R: Chronic myelogenous leukemia; age incidence, duration and benefit derived from irradiation. JAMA 1924 (82):1489–1494
Gollerkeri MP, Shah GB: Management of chronic myeloid leukemia. A five-year survey with a comparison of oral busulfan and splenic irradiation. Cancer 1971 (27):596–601
Baker M, Taub RN, Carter WH Jr et al. and the Toronto Leukemia Study Group: Immunotherapy for chronic myelogenous leukemia: Survival not affected by treatment in the stable phase. Cancer Res 1984 (44):383–385
Arlin ZA, Mertelsmann R, Berman E et al.: 13-Cis-retinoic acid does not increase the true remission rate and the duration of true remission (induced by cytotoxic chemotherapy) in patients with chronic phase chronic myelogenous leukemia. J Clin Oncol 1985 (4):473–476
Advani SH, Gulwani B, Ghogale SG et al.: Effect of administration of BCG, levamisole and irradiated leukemic cells on immune status and remission status in chronic myelogenous leukemia. Oncology 1985 (42):275–281
Medical Research Council’s Working Party for Therapeutic Trials in Leukaemia: Chronic granulocytic leukaemia. Comparison of radiotherapy and busulphan therapy. Brit Med J 1968 (1):201–208
Ihde DC, Canellos GP, Schwartz JH et al.: Splenectomy in the chronic phase of chronic granulocytic leukemia. Effects in 32 patients. Ann Intern Med 1976 (84):17–21
Spiers ASD, Galton DAG, Kaur J et al.: Thioguanine as primary treatment for chronic granulocytic leukaemia. Lancet 1975 (l):829–832
Singer CRJ, McDonald GA, Douglas AS: Twenty-five year survival of chronic granulocytic leukaemia with spontaneous karyotype conversion. Brit J Haemat 1984 (57):309–313
Zago MA, Costa FF, Bottura C: Cytogenetic remission in a Ph-positive case of chronic myelogenous leukaemia. Scand J Haemat 1979 (22):91–95
Hester JP, Waddell CC, Coltman CA Jr et al.: Response of chronic myelogenous leukemia patients to COAP- splenectomy. Cancer 1984 (54):1977–1982
Kantarjian HM, Vellekoop L, McCredie KB et al.: Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. J Clin Oncol 1985 (3):192–200
Fever A, Cheever MA, Greenberg BP et al.: Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. N Engl J Med 1982 (306):63–68
Goldman JM, Apperley JF, Jones L et al.: Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986 (314):202
Mahmoud HK, Schaefer UW, Schuening F et al.: Bone marrow transplantation for chronic granulocytic leukemia. Klin Wschr 1985 (63):560–564
Thomas ED, Clift RA, Fefer A et al.: Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986 (104):155–163
Greenberg PL, Mosny SA: Cytotoxic effects of interferon in vitro on granulocytic progenitor cells. Cancer Res 1977 (37):1794–1799
Verma DS, Spitzer G, Gutterman JU et al.: Human leukocyte interferon preparation blocks granulopoietic differentiation. Blood 1979 (54):1423–1427
Taetle R, Buick RN, McCulloch EA: Effect of interferon on colony formation in culture by blast cell progenitors in acute myeloblasts leukemia. Blood 1980 (56):549–552
Williams CKO, Svet-Moldavskaya I, Vilcek J et al.: Inhibitory effects of human leukocyte and fibroblast interferons on normal and chronic myelogenous leukemic granulocytic progenitor cells. Oncology 1981 (38):356–360
Neumann HA, Fauser AA: Effect of interferon on pluripotent hemopoietic progenitors (CFU-GEMM) derived from human bone marrow. Exp Hematol 1982 (10):587–590
Broxmeyer HE, Lu L, Platzer E et al.: Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 1983 (131):1300–1305
Tomida M, Yamamoto Y, Hozumi M: Stimulation by interferon of induction of differentiation of human promyelocyte leukemia cells. Biochem Biophys Res Commun 1982 (104):30–37
Perussia B, Dayton ET, Fanning P et al.: Immune interferon and leukocyte-conditioned medium induce normal and leukemic myeloid cells to differentiate along the monocytic pathway. J Exp Med 1983 (158):2058–2080
Gutterman JU, Blumenschein GR, Alexanian R et al.: Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med 1980 (93):399–406
Niederle N, Kurschel E, Schmidt CG: Biologischer Effekt von rekombiniertem Leukozyten-alpha2-lnterferon bei metastasierten kolorektalen Karzinomen. Dtsch med Wschr 1984 (109):779–782
Quesada JR, Swanson DA, Trindade A et al.: Renal cell carcinoma: Antitumor effects of leukocyte interferon. Cancer Res 1983 (43):940–943
Talpaz M, McCredie KB, Keating MJ et al.: Clinical investigation of leukocyte interferon (HulFN-alpha) in chronic myelogenous leukemia. Blood 1983 (62):209a
Talpaz M, McCredie KB, Mavligit GM et al.: Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983 (62):689–692
Talpaz M, McCredie K, Kantarjian H et al.: Chronic myelogenous leukaemia: Haematological remissions with alpha interferon. Brit J Haematol 1986 (64):87–95
Rohatiner AZS, O’Brien M, Dhaliwal MS et al.: Experience with recombinant DNA interferon (IFN-alpha2) in patients with chronic leukaemia. 13th International Congress of Chemotherapy 1983:266/9–15, Vienna
Talpaz M, Kantarjian HM, McCredie KB et al.: Hematologic remission and cytogenetic improvement induced by recombinant human interferon alphaA in chronic myelogenous leukemia. N Engl J Med 1986 (314):1065–1069
Diedrich H, von Wussow P, Freund M et al.: Treatment of chronic myelogenous leukemia with recombinant interferon alpha 2. Blut 1986 (53):236
Niederle N, Kloke O, May D et al.: Treatment of chronic myelogenous leukemia with recombinant interferon alpha 2b. Invest New Drugs (in press)
Gastl G, Aulitzky W, Tilg H et al.: Dose-related effectiveness of alpha interferon in chronic myelogenous leukemia. Blut (in press)
Morra E, Alimena G, Liberati AM et al.: Recombinant alpha 2 interferon (rIFN alpha2) in the treatment of chronic myelogenous leukemia. In: Program and Abstracts, 4th International Symposium on Therapy of Acute Leukemias, 299 (318), Roma 7–12 Feb. 1987
Kurzrock R, Talpaz M, Kantarjian H et al.: Phase II study of recombinant interferon-gamma in chronic myelogenous leukemia. Blood 1986 (68, Suppl 1):255a
Herrmann F, Lindemann A, Bambach T et al.: Recombinant interferon-gamma (rIFN-gamma) in benign phase CML: In vivo and in vitro results. In: Program and Abstracts, 4th International Symposium on Therapy of Acute Leukemias, 230 (184), Rome, 7–12 Feb, 1987
Talpaz M, Trujillo JM, Hittelman WN et al.: Suppression of clonal evolution in two chronic myelogenous leukaemia patients treated with leukocyte interferon. Brit J Haematol 1985 (60):619–624
Niederle N, Kloke O, Doberauer C et al.: Alpha-Interferon: Erste Behandlungsergebnisse bei der chronischen myeloischen Leukaemie. Dtsch med Wschr 1986 (111):767–772
Geissler G, Gastl G, Konwalinka G et al.: Antileukemic effect of rIFN-alpha in CML: Comparison in vitro and in vivo. Blut 1986 (53):239–240
Talpaz M, Mavligit G, Keating M et al.: Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Int Med 1983 (99):789–792
Niederle N, Kloke O, Osieka R et al.: Interferon alpha-2b in the treatment of chronic myelogenous leukemia. Semin Oncol (in press)
Wandl UB, Niederle N, Kloke O et al.: Chronic myelocytic leukaemia: Reduction of in vitro proliferation of haemopoietic progenitor cells in patients treated with recombinant alpha-interferon (IFN-alpha 2b). Blut 1986 (53):237
Kloke O, Becher R, Niederle N: Response to the combined administration of interferons alpha and gamma after failure of single interferon therapy in chronic myelogenous leukaemia. Blut (submitted)
Maxwell BL, Talpaz M, Gutterman JU: Down regulation of peripheral blood cell interferon receptors in chronic myelogenous leukaemia patients undergoing human interferon (HulFN) therapy. Int J Cancer 1985 (36):23–28
Bergsagel DE, Haas RH, Messner HA: Interferon alpha-2b in the treatment of chronic granulocytic leukemia. Sem Oncol 1986 (13, Suppl 2):29–34
Espinosa E, De Castro R, Carnot J et al.: Treatment of chronic myelocytic leukemia with human leukocyte alpha interferon. Abstr2nd Cuban Sem Interferon Biotechnol, Havana 1986
Kantarjian H, Talpaz M, Keating M et al.: Therapy of Philadelphia chromosome positive chronic myelogenous leukemia with initial intensive chemotherapy (DOAP) followed by maintenance with human leukocyte alpha interferon (IFN-A). Blood 1986 (68, Suppl 1):224a
Silver RT, Reich SD, Coleman M et al.: Gamma interferon has activity in treating chronic myeloid leukemia. Blood 1986 (68, Suppl 1):232a
Fleischmann WR, Fleischmann CM, Fiers W: Potentiation of interferon action by mixtures of recombinant DNA- derived human interferons. Antiviral Res 1984 (4):357–360
Denz H, Lechleitner M, Marth C et al.: Effect of human recombinant alpha 2 and gamma interferon on the growth of human cell lines from solid tumors and hematological malignancies. J Interferon Res 1985 (5):147–157
McPherson TA, Tan YH: Phase I pharmatoxicology study of human fibroblast interferon in human cancers. J Natl Cancer Inst 1980 (65):75–79
Niederle N, Kurschel E, Schuette J et al.: Phase I study of human interferon gamma in patients with advanced cancer. In: Kirchner H and Schellekens K (eds) The biology of the interferon system 1984. Elsevier Science Publishers, Amsterdam 1985 pp 509–515
Foon KA, Sherwin SA, Abrams PG et al.: A Phase I trial of recombinant gamma interferon in patients with cancer. Cancer Immunol Immunother 1985 (20):193–197
Vadhan-Raj S, Nathan CF, Sherwin SA et al.: Phase I trial of recombinant interferon gamma by 1-hour iv infusion. Cancer Treat Rep 1986 (70):609–614
Kurzrock R, Quesada JR, Talpaz M et al.: Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. J Clin Oncol 1986 (4):1101–1109
Quesada JR, Talpaz M, Rios A et al.: Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 1986 (4):234–243
Averbuch SD, Austin HA, Sherwin SA et al.: Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides. N Engl J Med 1984 (310):32–35
Selby P, Kohn J, Raymond J et al.: Nephrotic syndrome during treatment with interferon. Br Med J 1985 (290):1180
Metz U, Kruschel E, Niederle N et al.: Urinary enzymes in the detection of the nephrotoxic potential of recombinant human alpha-interferon. In: Bach PH, Look EA (eds) Renal heterogeneity and target cell toxicity. John Wiley & Sons, Chichester-New York-Brisbane-Toronto-Singapore 1985 pp 267–270
Kurschel E, Metz-Kruschel U, Hofmann W et al.: Chronische myeloische Leukaemie - Untersuchungen zur Erfassung der Nephrotoxizitaet von humanem alpha-2b Interferon unter besonderer Beruecksichtigung der Analyse von Harnenzymen. Klin Wschr (in press)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Niederle, N., Kloke, O. (1987). Interferon in the Treatment of Hairy Cell Leukemia and Chronic Myelogenous Leukemia. In: Smyth, J.F. (eds) Interferons in Oncology. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72805-1_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-72805-1_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-72807-5
Online ISBN: 978-3-642-72805-1
eBook Packages: Springer Book Archive